LYPLA2L: A Potential Drug Target and Biomarker (G653639)

Target Name: LYPLA2P1

NCBI ID: G653639

LYPLA2P1

Other Name(s): LYPLA2L | APT | Lysophospholipase II pseudogene 1 | dJ570F3.6 | LYPLA2 pseudogene 1

LYPLA2L: A Potential Drug Target and Biomarker

Introduction

LYPLA2L (long non-coding RNA-protein interaction protein 2-like) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been involved in various cellular processes , including cell cycle progression, migration, and invasion. LYPLA2L has also been shown to be involved in the regulation of inflammation and has been linked to the development of various diseases, such as cancer.

Potential Drug Target

The potential drug target for LYPLA2L is its role in cell adhesion and the regulation of cell cycle progression. It is known to play a role in the regulation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and function. LYPLA2L is also involved in the regulation of the actin-associated protein 2 (AAP2), which is a protein that helps to maintain the integrity of actin filaments in cells.

Additionally, LYPLA2L has been shown to be involved in the regulation of cell cycle progression by inhibiting the activity of the protein kinase IP3-CREB-associated protein 1 (IP3-CREB-AP1). This protein is known to play a role in the regulation of the immune response and has been linked to the development of cancer. By inhibiting IP3-CREB-AP1 activity, LYPLA2L may be able to prevent the progression of cancer cells through the cell cycle.

Biomarker

LYPLA2L has also been shown to be involved in the regulation of inflammation and has been linked to the development of various diseases, such as cancer. It has been shown to play a role in the regulation of T cell development and has been linked to the development of T-cell acute lymphoblastic leukemia (T-ALL).

Additionally, LYPLA2L has been shown to be involved in the regulation of macrophage function. Macrophages are a type of white blood cell that play a key role in the immune response and have been linked to the development of various diseases , such as cancer. LYPLA2L has been shown to play a role in the regulation of phagocytosis of macrophages and has been linked to the development of cancer.

Conclusion

LYPLA2L is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell adhesion, cell cycle progression, and inflammation. Its potential drug target is its role in cell adhesion and the regulation of cell cycle progression, as well as its involvement in the regulation of inflammation. Additionally, LYPLA2L has also been shown to be involved in the regulation of T cell development and macrophage function. Further research is needed to fully understand the potential of LYPLA2L as a drug target and biomarker.

Protein Name: LYPLA2 Pseudogene 1

The "LYPLA2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYPLA2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets